File Name: .pdf
Size: 6175 KB
Status: AVAILABLE Last checked: 29 Minutes ago!
Rating: 4.4/5 from 672 votes.
Dr. Raphael Bueno is that the Chief, Division of body part Surgery and Vice Chair of Surgery for Cancer and travel analysis at Boston’s Brigham and Women’s Hospital, a teaching affiliate of the Harvard University school of medication wherever Dr. Bueno additionally is academician of Surgery. As a 1985 graduate of Harvard graduate school, Dr. Bueno completed a residency program at Brigham and Women’s Hospital and a fellowship in body part Surgery at the Massachusetts General Hospital.
Board certified in 1993, Dr. Bueno spent a lot of of his early career teaching at the Harvard Medical school throughout the 1990’s. Much of Dr. Bueno’s newer focus has been treating patients of malignant carcinoma and carcinoma at varied stages. Dr. Bueno has studied extensively the behavior of all kinds of carcinoma (including serosa carcinoma and pericardiac carcinoma) at a cellular level with hopes of group action his growing data of cell-level behavior into additional aggressive and effective mesothelioma treatment regimens.
Professional Highlights/Clinical analysis
Dr. Bueno’s current analysis initiatives embrace the investigation of latest targets for carcinoma and carcinoma therapies, furthermore because the development of tests aimed toward police investigation cancer and distinctive the prognosis of patients with body part malignancies following surgery. he’s the lead investigator of many current clinical trials, one in every of that is examining biomarker responses in growth tissue in surgical patients with malignant serosa carcinoma.
Dr. Bueno serves these days as Program and director of research of the International carcinoma Program (IMP) at Brigham and Women’s Hospital/Harvard Medical School—the largest program of its kind within the world that was based with the mission of providing patients with malignant serosa carcinoma the foremost innovative and advanced treatment regimens on the market. Much of Dr. Bueno’s analysis has been printed in national medical journals, as well as the Journal of body part vessel Surgery. Among the topics explored in his publications square measure the molecular pathways and therapeutic targets in carcinoma, chemotherapeutical drug resistance in primary malignant serosa carcinoma, and organic phenomenon magnitude relation testing targeting the classification of traditional respiratory organ vs. respiratory organ tumors. U.S. News and World Report has recently lauded Dr. Bueno’s analysis in their doc rankings. Patients with malignant carcinoma square measure urged to explore if Dr. Bueno’s experience within the field is also useful to them.
Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, Salgia R. Molecular pathways and therapeutic targets in carcinoma. Oncotarget. 2014 Mar twenty one.
Mohiuddin K, Haneuse S, Sofer T, Gill R, Jaklitsch MT, Colson YL, Wee J, Bueno R, Mentzer SJ, Sugarbaker DJ, Swanson SJ. Relationship between margin distance and native return among patients undergoing wedge surgical process for little (â‰¤2 cm) non-small cell carcinoma. J Thorac Cardiovasc Surg. 2014 Apr;147(4):1169-75; discussion 1175-7.
Opitz I, Bueno R, Lim E, Pass H, Pastorino U, Boeri M, Rocco G, Biomolecular and clinical observe in malignant serosa carcinoma and respiratory organ cancer: what body part surgeons ought to apprehend. European Journal Of Cardio body part Surgery : Official Journal Of the eu Association For Cardio body part Surgery. 2014 Mar twelve.
De Rienzo A, Yeap BY, Cibas ES, I. A. Richards WG, Dong L, Gill RR, Sugarbaker DJ, Bueno R. organic phenomenon magnitude relation check distinguishes traditional respiratory organ from respiratory organ tumors in solid tissue and FNA biopsies. J metric weight unit Diagn. 2014 Mar;16(2):267-72.
Chirieac LR, Barletta JA, Yeap BY, I. A. Richards WG, Tilleman T, Bueno R, Baldini EH, Godleski J, Sugarbaker DJ. Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin cancer. J Clin Oncol. 2013 Dec 20;31(36):4544-9.
De Rienzo A, I. A. Richards WG, Yeap BY, Coleman MH, Sugarbaker letter of the alphabet, Chirieac LR, Wang YE, Quackenbush J, Jensen RV, Bueno R. sequent Binary cistron magnitude relation Tests outline a completely unique Molecular Diagnostic Strategy for Malignant serosa carcinoma. Clin Cancer Res. 2013 Gregorian calendar month eighteen.
Lee MS, Mamon HJ, Hong TS, Choi NC, Fidias PM, Kwak EL, Meyerhardt JA, Ryan DP, Bueno R, Donahue DM, Jaklitsch MT, Lanuti M, Rattner DW, Fuchs CS, Enzinger computer. operative cetuximab, irinotecan, Cisplatin, and irradiation for patients with domestically advanced muscular structure cancer. Oncologist. 2013;18(3):281-7.
Sugarbaker DJ, Gill RR, Yeap BY, Wolf AS, DaSilva MC, Baldini EH, Bueno R, I. A. Richards WG. Hyperthermic intraoperative serosa cisplatin therapy extends interval to return and survival among low-risk patients with malignant serosa carcinoma undergoing surgical macroscopical complete surgical process. J Thorac Cardiovasc Surg. 2013 Apr;145(4):955-63.
Rusch V, Baldini EH, Bueno R, DE Perrot M, Flores R, Hasegawa S, Klepetko W, Krug L, Lang-Lazdunski L, Pass H, Weder W, Sugarbaker DJ, The role of surgical cytoreduction within the treatment of malignant serosa mesothelioma: meeting outline of the International carcinoma interest Congress, Sept 11-14, 2012, Boston, Mass. J Thorac Cardiovasc Surg. 2013 Apr;145(4):909-10.
Barbone D, Cheung P, Battula S, Busacca S, Gray SG, Longley DB, Bueno R, Sugarbaker DJ, Fennell DA, Broaddus VC. Vorinostat eliminates cellular resistance of carcinoma 3D spheroids via restoration of Noxa expression. PLoS ONE. 2012;7(12):e52753.
Sugarbaker DJ, Wolf AS, Chirieac LR, Godleski JJ, Tilleman TR, Jaklitsch MT, Bueno R, I. A. Richards WG. Clinical and pathological options of three-year survivors of malignant serosa carcinoma following extrapleural cutting out. European Journal Of Cardio body part Surgery : Official Journal Of the eu Association For Cardio body part Surgery. 2011 Feb 8.
Ou WB, Hubert C, Corson JM, Bueno R, Flynn DL, Sugarbaker DJ, playwright JA. Targeted inhibition of multiple receptor amino acid kinases in carcinoma. Neoplasia. 2011 Jan;13(1):12-22.
De Rienzo A, Dong L, Yeap BY, Jensen RV, I. A. Richards WG, Gordon GJ, Sugarbaker DJ, Bueno R. Fine-needle aspiration biopsies for organic phenomenon ratio-based diagnostic and prognostic tests in malignant serosa carcinoma. Clin Cancer Res. 2011 Gregorian calendar month 15;17(2):310-6.